Experienced in Hyperparathyroidism

Geoffrey C. Chong

Melbourne, VIC, AU 
Experienced in Hyperparathyroidism
Melbourne, VIC, AU 
OverviewLocationsClinical Research

Overview

Geoffrey Chong practices in Melbourne, Australia. Mr. Chong is rated as an Experienced expert by MediFind in the treatment of Hyperparathyroidism. His top areas of expertise are Follicular Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Parathyroidectomy.

His clinical research consists of co-authoring 43 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Hyperparathyroidism.

Gender
Male

Locations

Melbourne, VIC, Australia
Other Locations
Northern Health
Epping, NSW, Australia
Ballarat, VIC, Australia
Heidelberg, VIC, Australia
Epping, VIC, Australia
Austin Health, VIC, Australia
Ballarat Central, VIC, Australia
Canberra, ACT, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Enrollment Status: Terminated
Publish Date: August 28, 2025
Intervention Type: Drug
Study Drugs: Brentuximab, Doxorubicin, Vinblastine, Dacarbazine, Nivolumab, Filgrastim
Study Phase: Phase 2
A Randomised Phase III Open Label Study of Regorafenib + Nivolumab vs Standard Chemotherapy in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)
A Randomised Phase III Open Label Study of Regorafenib + Nivolumab vs Standard Chemotherapy in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)
Enrollment Status: Active_not_recruiting
Publish Date: July 17, 2025
Intervention Type: Drug, Biological
Study Drugs: Regorafenib, Nivolumab, Docetaxel, Paclitaxel, Irinotecan, Trifluridine/Tipracil
Study Phase: Phase 3
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial To Compare The Efficacy And Safety Of Fruquintinib Plus Best Supportive Care To Placebo Plus Best Supportive Care In Patients With Refractory Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: Fruquintinib
Study Phase: Phase 3
Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers - An International, Multi-Center, Double Blind, Randomized Placebo Controlled Phase III Trial
Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers - An International, Multi-Center, Double Blind, Randomized Placebo Controlled Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: February 02, 2024
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer
Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer
Enrollment Status: Completed
Publish Date: August 27, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

43 Total Publications

Immunotherapy in gastric adenocarcinoma - a rapidly evolving treatment landscape.
Immunotherapy in gastric adenocarcinoma - a rapidly evolving treatment landscape.
Journal: Critical reviews in oncology/hematology
Published: July 31, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Chong's expertise for a condition
ConditionClose
    View All 12 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile